Products for Research Use Only

RVX-297

CAT: 0804-HY-114504-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-114504-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
RVX-297 is a potent, orally active BET bromodomain inhibitor with selectivity for BD2. RVX-297 shows IC50s of 0.08, 0.05, and 0.02 μM for BRD2 (BD2), BRD3 (BD2), and BRD4 (BD2), respectively. RVX-297 suppresses inflammatory gene expression in multiple immune cell types. RVX-297 is effective in acute inflammation and autoimmunity models[1][2].
CAS Number
1044871-04-6
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
COVID-19-anti-virus
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/rvx-297.html
Purity
95.00
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1NC(C2=CC(C)=C(OCCN3CCCC3)C(C)=C2)=NC4=C1C(OC)=CC(OC)=C4
Molecular Formula
C24H29N3O4
Molecular Weight
423.50
Precautions
H302, H312, H332
References & Citations
[1]Jahagirdar R, et al. RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease. Mol Pharmacol. 2017;92 (6) :694-706.|[2]Kharenko OA, et al. RVX-297- a novel BD2 selective inhibitor of BET bromodomains. Biochem Biophys Res Commun. 2016;477 (1) :62-67.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD2; BRD3; BRD4; BRDT